Modified coagulation factor VIIa with extended half-life

US8765915B2 · kind B2 · utility

Assignee

• CSL Behring AG · DE

Inventors

• Thomas Weimer · Gladenbach, DE
• Stefan Schulte · Marburg, DE
• Ulrich Kronthaler · Deisenhofen, DE
• Wiegand Lang · Cölbe, DE
• Uwe Liebing · Dömitz, DE
• Wilfried Wormsbacher · Kirchhain, DE

Key dates

• Filing date: Feb 3, 2007
• Grant date: Jul 1, 2014
• Expiry date: May 15, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.